GRI Bio Presents Positive Preclinical Data Demonstrating GRI-0621’s Ability to Inhibit Invariant Natural Killer T (iNKT) Cell Activity and Reduce Important Inflammatory and Fibrotic Drivers in Idiopathic Pulmonary Fibrosis (IPF)
16. Oktober 2024 08:45 ET
|
GRI Bio, Inc.
Data suggest that NKT cells are activated in airways in Idiopathic Pulmonary Fibrosis (IPF) patients and inhibition of iNKT cell activity can treat bleomycin-induced pulmonary fibrosis ...
Processa Pharmaceuticals Announces Positive Preclinical Data for NGC-Iri
19. August 2024 08:00 ET
|
Processa Pharmaceuticals, Inc.
Delivers more cancer-killing SN-38 molecules to tumor than irinotecan and Onivyde® Studies support potential benefit as an improved treatment with fewer side effects HANOVER, Md., Aug. 19, 2024 ...
GRI Bio Announces Publication of Positive Preclinical Data from Lead Program GRI-0621 in the American Journal of Respiratory and Critical Care Medicine
02. Juli 2024 09:05 ET
|
GRI Bio, Inc.
Data demonstrates that NKT cells are activated in airways in IPF patients and inhibition of type 1 invariant NKT (iNKT) cell activity can ameliorate bleomycin-induced pulmonary fibrosis in mice ...
GRI Bio (NASDAQ: GRI) Participates in Virtual Investor “What This Means” Segment Highlighting Positive Preclinical Data from Idiopathic Pulmonary Fibrosis (IPF) and Systemic Lupus Erythematosus (SLE) Programs
22. Mai 2024 09:15 ET
|
GRI Bio, Inc.
Data recently presented at the 2024 American Thoracic Society International Conference and the 14th International Congress on Autoimmunity Company reiterates 2024 as year of data Click here to...
GT Biopharma Presented Positive Preclinical Data for GTB-5550, a Novel TriKE® Molecule for Targeted Prostate Cancer Treatment During the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting
06. November 2023 09:30 ET
|
GT Biopharma, Inc.
BRISBANE, CALIFORNIA, Nov. 06, 2023 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the...
Mithra Announces New Positive Preclinical Data from CSF-1R Inhibitor Program
15. Juni 2023 01:30 ET
|
Mithra Pharmaceuticals
Mithra Announces New Positive Preclinical Data from CSF-1R Inhibitor Program CSF-1R inhibitors show promising anti-tumor activityLead compound shows synergy with PD1 cancer immune checkpoint...